<?xml version='1.0' encoding='utf-8'?>
<document id="17199019"><sentence text="Brivaracetam (UCB 34714)."><entity charOffset="0-12" id="DDI-PubMed.17199019.s1.e0" text="Brivaracetam" /></sentence><sentence text="Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra)"><entity charOffset="0-12" id="DDI-PubMed.17199019.s2.e0" text="Brivaracetam" /><entity charOffset="50-63" id="DDI-PubMed.17199019.s2.e1" text="levetiracetam" /><entity charOffset="65-68" id="DDI-PubMed.17199019.s2.e2" text="LEV" /><pair ddi="false" e1="DDI-PubMed.17199019.s2.e0" e2="DDI-PubMed.17199019.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17199019.s2.e0" e2="DDI-PubMed.17199019.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17199019.s2.e0" e2="DDI-PubMed.17199019.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17199019.s2.e1" e2="DDI-PubMed.17199019.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17199019.s2.e1" e2="DDI-PubMed.17199019.s2.e2" /></sentence><sentence text=" It possesses a binding affinity for the synaptic vesicle protein 2A (SV2A) ten-fold above that of LEV and also shows an ability to inhibit Na+ channels"><entity charOffset="140-143" id="DDI-PubMed.17199019.s3.e0" text="Na+" /><entity charOffset="99-101" id="DDI-PubMed.17199019.s3.e1" text="LEV" /><pair ddi="false" e1="DDI-PubMed.17199019.s3.e1" e2="DDI-PubMed.17199019.s3.e1" /><pair ddi="false" e1="DDI-PubMed.17199019.s3.e1" e2="DDI-PubMed.17199019.s3.e0" /></sentence><sentence text=" This correlates with a higher potency in suppressing epileptiform responses in vitro and a more potent and complete suppression of different seizure types in animals with an acquired or genetic epilepsy" /><sentence text=" Brivaracetam has been tested in a comprehensive safety pharmacology, toxicology, developmental toxicology, and genotoxicity program"><entity charOffset="1-13" id="DDI-PubMed.17199019.s5.e0" text="Brivaracetam" /></sentence><sentence text=" It is of low acute toxicity, target organ for toxic effects is the hepatobiliary tract" /><sentence text=" Carcinogenicity studies are ongoing" /><sentence text=" Human pharmacology studies have shown that brivaracetam has a half-life of 8 h and nearly complete bioavailability"><entity charOffset="44-56" id="DDI-PubMed.17199019.s8.e0" text="brivaracetam" /></sentence><sentence text=" Brivaracetam is primarily metabolized via hydrolysis of the acetamide group and CYP2C8-mediated hydroxylation"><entity charOffset="1-13" id="DDI-PubMed.17199019.s9.e0" text="Brivaracetam" /><entity charOffset="61-70" id="DDI-PubMed.17199019.s9.e1" text="acetamide" /><pair ddi="false" e1="DDI-PubMed.17199019.s9.e0" e2="DDI-PubMed.17199019.s9.e0" /><pair ddi="false" e1="DDI-PubMed.17199019.s9.e0" e2="DDI-PubMed.17199019.s9.e1" /></sentence><sentence text=" Its metabolites are not pharmacologically active" /><sentence text=" Excretion of over 95% of the dose, including metabolites, occurs renally within 72 h" /><sentence text=" Healthy volunteer studies demonstrated a favorable tolerability profile" /><sentence text=" Treatment emergent adverse events were mild to moderate, mostly of CNS origin, and resolved within 24 hrs, with decreasing incidence after repeated intake" /><sentence text=" Drug-drug interaction studies with high dose of brivaracetam (400 mg/d) showed a dose-dependent increase of carbamazepine-epoxide levels"><entity charOffset="49-61" id="DDI-PubMed.17199019.s14.e0" text="brivaracetam" /><entity charOffset="109-122" id="DDI-PubMed.17199019.s14.e1" text="carbamazepine" /><entity charOffset="123-130" id="DDI-PubMed.17199019.s14.e2" text="epoxide" /><pair ddi="false" e1="DDI-PubMed.17199019.s14.e0" e2="DDI-PubMed.17199019.s14.e0" /><pair ddi="false" e1="DDI-PubMed.17199019.s14.e0" e2="DDI-PubMed.17199019.s14.e1" /><pair ddi="false" e1="DDI-PubMed.17199019.s14.e0" e2="DDI-PubMed.17199019.s14.e2" /><pair ddi="false" e1="DDI-PubMed.17199019.s14.e1" e2="DDI-PubMed.17199019.s14.e1" /><pair ddi="false" e1="DDI-PubMed.17199019.s14.e1" e2="DDI-PubMed.17199019.s14.e2" /></sentence><sentence text=" No significant interaction with low doses of phenytoin was observed at the same high dose levels of brivaracetam, and only a moderate pharmacokinetic interaction with an oral contraceptive, without impact on hormonal levels or ovulation, was observed"><entity charOffset="46-55" id="DDI-PubMed.17199019.s15.e0" text="phenytoin" /><entity charOffset="101-113" id="DDI-PubMed.17199019.s15.e1" text="brivaracetam" /><pair ddi="false" e1="DDI-PubMed.17199019.s15.e0" e2="DDI-PubMed.17199019.s15.e0" /><pair ddi="false" e1="DDI-PubMed.17199019.s15.e0" e2="DDI-PubMed.17199019.s15.e1" /></sentence><sentence text=" The pharmacokinetic profile of brivaracetam is unaltered in elderly subjects or those with impaired renal function"><entity charOffset="32-44" id="DDI-PubMed.17199019.s16.e0" text="brivaracetam" /></sentence><sentence text=" Clearance of brivaracetam is reduced in patients with hepatic insufficiency"><entity charOffset="14-26" id="DDI-PubMed.17199019.s17.e0" text="brivaracetam" /></sentence><sentence text=" In the photoparoxysmal response model in patients with photosensitive epilepsy brivaracetam was effective at all tested doses (10 - 80 mg) in reducing or abolishing EEG discharges evoked by a photic stimulus" /><sentence text=" Phase 2 studies in patients with refractory partial onset seizures have recently been completed" /><sentence text="" /></document>